NEUTRALIZING ANTI-SARS- COV-2 ANTIBODIES AND METHODS OF USE THEREOF
This disclosure provides novel neutralizing anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof. The disclosed anti-SARS-CoV-2 antibodies constitute a novel therapeutic strategy in protection from SARS-CoV-2 infections..
Medienart: |
Patent |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Europäisches Patentamt - (2024) vom: 13. März Zur Gesamtaufnahme - year:2024 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
NUSSENZWEIG MICHEL [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-03-13, Last update posted on www.tib.eu: 2024-04-16, Last updated: 2024-04-19 |
---|
Patentnummer: |
EP4334343 |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
EPA001209868 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | EPA001209868 | ||
003 | DE-627 | ||
005 | 20240419123231.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240322s2024 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)EPA001209868 | ||
035 | |a (EPA)EP4334343 | ||
035 | |a (EPA)81750770 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 0 | |a NUSSENZWEIG MICHEL |e verfasserin |4 aut | |
245 | 1 | 0 | |a NEUTRALIZING ANTI-SARS- COV-2 ANTIBODIES AND METHODS OF USE THEREOF |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: www.epo.org (no modifications made), First posted: 2024-03-13, Last update posted on www.tib.eu: 2024-04-16, Last updated: 2024-04-19 | ||
520 | |a This disclosure provides novel neutralizing anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof. The disclosed anti-SARS-CoV-2 antibodies constitute a novel therapeutic strategy in protection from SARS-CoV-2 infections. | ||
650 | 4 | |a bio | |
650 | 4 | |a tec | |
650 | 4 | |a G01N: Investigating or analysing materials by determining their chemical or physical properties (measuring or testing processes other than immunoassay, involving enzymes or microorganisms c12m, c12q) | |
650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
650 | 4 | |a che | |
650 | 4 | |a 615 | |
773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 13. März |
773 | 1 | 8 | |g year:2024 |g day:13 |g month:03 |
856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/81750770/publication/EP4334343A1?q=EP4334343 |x 0 |z kostenfrei |3 Volltext |
912 | |a GBV_EPA | ||
951 | |a AR | ||
952 | |j 2024 |b 13 |c 03 |